The Granite List Live

Continuing our ASCEND Conference Series, Ed Ligonde, Executive Vice President of Nielson Benefits Group, stops by to talk with Sally about trend he's picked up while attending the conference such as a push for transparency and the second opinion process. He also discusses how the Mastermind ecosystem has helped him and his career through collaboration and knowledge sharing.

Continuing our ASCEND Conference series, Dan LaBroad, CEO of Ovation Health & Life Services, discusses his journey to where he ended up now. Attending the ASCEND and Mastermind conferences are a major factor in his successes by connecting him with like-minded people who help find solutions, support each other, and want the best for their people. Dan shares 2023 trends into giving his clients and partners better quality care, better access to care while providing lower costs.

Continuing our ASCEND Conference series, Doug Geinzer stops by tell us how Coral is utilizing cost-containment in a way that still provides high quality surgeries for their clients. He also discusses how the ASCEND Conference has allowed him and other advisors to come together to talk bounce ideas off of each other and learn more about what it takes to get win more business.

We're still live from the ASCEND Conference in New Orleans. Mastermind Tammera Hollerich comes to talk with us about trends in the industry she's noticed through the conference and how the ASCEND program is helping brokers stay updated on top of these trends and strategies in the industry.

We're coming to you LIVE from this year's ASCEND Conference in New Orleans. To kick the series off, we sit down with Nelson Griswold to discuss the purpose of the conference and how it plays into his mission to reform and preserve the private health care system.

On the heels of the second annual DEI Summit, Leigh and Sally sit down with the Detroit Pistons' VP of Diversity, Equity and Inclusion, Stefen Welch, to explore lessons learned about the role DEI plays in growing a team....of employees. Stefen shares his personal story of growth as he rose in the corporate ranks. Today, he leans into his past challenges to drive future results for the team of employees around him.

Balance billing, out of network claims, and unbundled networks. These are just a few of the terms that are explored during this episode of The Granite List Live. Leigh and Sally sit down with Clay McCormack and Arthur Chapman to learn how Reliant Health Partners' fair market pricing method delivers superior results with minimum disruption to employees.

In this episode, Ty Gilmore of Work Right and Kevin Courtain of Fortis Construction join Leigh and Sally to dig into the topic of workplace safety. Ty brings experience from helping employers identify where there may be holes in a plan to identify unnecessary work comp claims, and Kevin shares the importance of getting buy in from the leadership team and what success looks like with a solid safety plan.

How is Advanced Primary Care different than traditional primary care? Joined by guest Kaley Wilkinson, SVP, Strategic Relationships for Proactive Md, we explore how advanced primary care means a provider is equipped to care for the whole person – mentally, physically, emotionally, and socially – and that person is at the center of the care model. For employers and advisors alike, this is truly a cost containment strategy built around each employer’s unique employee population and claims data. Listen as Leigh and Sally guide the conversation around this important topic.

Live at the SIIA 2022 Engage Conference, we have our special guest Jeff Kelly, President at Buckingham Self-Funded Solutions. During this visit with host, Sally Pace, Jeff explains how gene therapy crosses over into stop loss. "Gene therapy translating into stop loss is the equivalent of profitability versus loss. As a stop loss carrier retaining a set threshold of risk and these gene therapy drugs coming out with the names that we have all heard, these million dollar price tags and such. I mean these are almost automatic claims to a stop so that these gene therapy drugs and the advanced biosimilar companies bringing in these cancer therapies and J codes, G codes, and every other code that we're about to become aware of. So bringing in cost contain measures stop-loss carriers are already acutely aware of this and they're already putting together solutions. So gene therapy is unfortunately here to stay. It will be evolving throughout the future." Learn more in this episode of The Granite List Live.